Elekta (OTCMKTS:EKTAY) Shares Gap Up - Here's What Happened

Key Points

• Elekta shares opened higher, rising from a prior close of $5.41 to $5.73, although trading volume was light at 507 shares.
• Zacks Research upgraded Elekta from “strong sell” to “hold,” bringing the stock’s overall analyst consensus to Hold.
• The company reported quarterly revenue of $372.3 million and earnings of $0.07 per share; analysts expect full-year EPS of $0.43, while Elekta continues to post a negative net margin.

Elekta AB (OTCMKTS:EKTAY - Get Free Report)'s share price gapped up before the market opened on Friday. The stock had previously closed at $5.41, but opened at $5.73. Elekta shares last traded at $5.73, with a volume of 507 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Elekta from a "strong sell" rating to a "hold" rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Hold rating. Based on data from MarketBeat, Elekta currently has an average rating of "Hold".

Elekta Price Performance

The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.62 and a current ratio of 0.86. The firm has a fifty day simple moving average of $5.39 and a two-hundred day simple moving average of $5.49. The firm has a market cap of $2.11 billion, a PE ratio of -47.75 and a beta of 1.03.

Elekta (OTCMKTS:EKTAY - Get Free Report) last issued its quarterly earnings data on Thursday, August 27th. The company reported $0.07 earnings per share (EPS) for the quarter. The business had revenue of $372.30 million for the quarter. Elekta had a positive return on equity of 13.47% and a negative net margin of 2.38%. Equities analysts predict that Elekta AB will post 0.43 EPS for the current fiscal year.

About Elekta

Elekta AB is a Sweden-based medical technology company that develops and supplies systems and software for radiation therapy, radiosurgery and related cancer-care applications. Its solutions are designed to help hospitals and clinics treat tumors while supporting more precise, personalized and less invasive care.

The company's portfolio includes linear accelerators, stereotactic radiosurgery systems, magnetic resonance-guided radiation therapy technology and brachytherapy products. Elekta also provides oncology information systems and workflow software, including platforms used for treatment planning, patient management and clinical data coordination.

Founded in 1972 by neurosurgeon and inventor Lars Leksell, Elekta initially focused on radiosurgery and later expanded into broader radiation oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.